Authors
Latest:
Exciting Developments in the Pipeline in HER2+ MBCA multidisciplinary panel of health care professionals and a patient advocate comment on their excitement about novel therapies in the pipeline for HER2-positive metastatic breast cancer.
Latest:
Biomarkers for Response to Anti–PD-1/Anti–PD-L1 Immune Checkpoint Inhibitors: A Large Meta-AnalysisArshiya Mariam, BS, and colleagues report the findings of a large meta-analysis assessing the ability of various biomarkers to predict responses to immune checkpoint inhibition.
Latest:
Cancer Network Faceoff: Conclusion of the Event and Presentation of AwardFinal remarks and presentation of awards.
Latest:
Clinical Pearls about the Referral Process of Bispecifics and CAR-T in RRMMThe discussion shares key takeaways and practical insights for optimizing the referral and treatment process for CAR T-cell and bispecific therapies.
Latest:
Opsoclonus-Myoclonus–Associated Neuroblastoma With Bone Marrow Metastases: What Would Be the Best Treatment Option?In this clinical quandary, investigators determine how to best treat patients with opsoclonus-myoclonus–associated neuroblastoma with bone marrow metastases.
Latest:
Frontline Setting of Pancreatic CancerPanelists discuss how the frontline treatment of pancreatic cancer typically involves chemotherapy regimens such as FOLFIRINOX (leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin) or gemcitabine-based therapies, with decisions guided by tumor characteristics, patient performance status, and treatment goals, aiming to improve survival outcomes and quality of life in newly diagnosed patients.
Latest:
Treatment of Multiple Myeloma: Q&A Session With Yale Cancer Center and SatellitesA Q&A session with the expert panel.
Latest:
Exploring Next-Line Options in HER2- MSS Gastric CancerExperts discuss other therapies or clinical trials that might be explored after trastuzumab deruxtecan, particularly for patients with HER2-positive microsatellite-stable (MSS) adenocarcinoma and progression on multiple lines of therapy.
Latest:
Marshall Posner, MD, on the Promise of Personalized mRNA Vaccines in Solid MalignanciesMarshall Posner, MD, detailed the potential for personalized mRNA vaccines to treat patients with various different tumors and what information is still needed.
Latest:
Unveiling Advances in GU Cancers: Insights from Oncology DecodedDive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.
Latest:
“Promising” Data Support Blinatumomab in CD19+ B-ALL PopulationOverall survival data with blinatumomab in the phase 3 E1910 study may be an “important development” in CD19-positive B-ALL.
